Association of acamprosate versus gabapentinoids with liver disease progression and alcohol-related admissions in patients with alcohol use disorder.

BACKGROUND: Alcohol-related liver disease (ALD) causes approximately one-fifth of all alcohol-related deaths. Only 4% of patients with alcohol use disorder (AUD) receive medications for AUD, such as acamprosate. Medications for AUD may decrease progr…

Preview only. Read the full abstract at the source